Chronic Lymphocytic Leukemia
8 competing products in clinical development for Chronic Lymphocytic Leukemia.
Pipeline by Phase
Phase 13
Phase 23
Phase 32
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Pirtobrutinib + Ibrutinib | Eli Lilly | Phase 3 | Recruiting | 47 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | Active | 44 |
| Pirtobrutinib | Eli Lilly | Phase 2 | Recruiting | 42 |
| OSI-461 | Astellas Pharma | Phase 2 | Completed | 35 |
| CP-461 | Astellas Pharma | Phase 1 | Completed | 29 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | Withdrawn | 27 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | Completed | 23 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | Withdrawn | 21 |